Frazier Healthcare Partners Launches Recida Therapeutics to Develop Novel Therapeutics for Serious Antibiotic-Resistant Infections

Novel-class LpxC inhibitor licensed from FUJIFILM Toyama Chemical
Co. Ltd.

$8.5M Series A financing led by Frazier

$4.4M awarded from CARB-X

Greater China rights partnered with MicuRx Pharmaceuticals, Inc.

MENLO PARK, Calif.–(BUSINESS WIRE)–Frazier Healthcare Partners today announced the launch of Recida
Therapeutics, Inc., a biopharmaceutical company focused on the
development of novel therapeutics for serious antibiotic-resistant
infections. Recida’s lead program, RC-01, is a novel, IND-stage LpxC
inhibitor for the treatment of multidrug-resistant gram-negative
infections. Recida has licensed development and commercialization rights
to RC-01 from FUJIFILM Toyama Chemical Co. Ltd. for all territories
outside Japan. Recida intends to a submit an Investigational New Drug
application (IND) for RC-01 to the U.S. Food and Drug Administration
(FDA) in the first quarter of 2019.

RC-01 inhibits bacterial LpxC, a key enzyme in Lipid A biosynthesis.
Lipid A is a key component of the outer membrane of gram-negative
bacteria and is therefore essential for bacterial survival. RC-01
exhibits a broad spectrum of rapid, in vitro and in vivo bactericidal
activity against major clinically relevant pathogens such as
the Enterobacteriaceae and Pseudomonas aeruginosa.
Notably, it is also very active in vitro against highly resistant P.
aeruginosa 
isolates from patients with cystic fibrosis. In
addition, RC-01 is active against Acinetobacter baumannii in
animal models of infection. Unlike previous LpxC inhibitors, RC-01 has
demonstrated a favorable pharmacokinetic profile with high drug
exposures as well as excellent preclinical safety and tolerability
across relevant species.

“We believe RC-01 is an exceptional asset around which to form Recida
Therapeutics,” said James Ge, MD, PhD, Chief Executive Officer and
co-founder of Recida. “LpxC inhibitors have long been a promising class
of antibiotics – and RC-01, if approved, would represent the first truly
novel antibiotic class to reach patients and physicians in more than 50
years. We believe the preclinical profile of RC-01 is best-in-class,
addresses the shortcomings of prior compounds, and has the potential to
be the first LpxC inhibitor to advance into later stages of clinical
development.”

CARB-X has awarded Recida up to $4.4M to help fund the preparation of an
IND application, a Phase 1 trial to be completed in 2019 and drug
product manufacturing to support subsequent Phase 2 studies. CARB-X
(Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, https://carb-x.org/)
is a Boston University global partnership funded by the U.S. Biomedical
Advanced Research and Development Authority (BARDA), the Wellcome
Trust, the U.K. Department of Health and Social Care’s Global
Antimicrobial Resistance Innovation Fund, and the Bill & Melinda Gates
Foundation, with in-kind support from National Institute of Allergy and
Infectious Diseases (NIAID), a part of the U.S. National Institutes of
Health (NIH).

Following Recida’s $8.5M Series A financing led by Frazier Healthcare
Partners, the company entered into a partnership with MicuRx
Pharmaceuticals, Inc. for development and commercialization of RC-01 in
the greater China region.

“In order to meet the critical and growing unmet need for novel
antibiotics, it is essential to collaborate broadly to advance promising
compounds like RC-01,” said David Socks, Executive Chairman of Recida
and Venture Partner of Frazier Healthcare Partners. “As a result, we are
grateful for our partnerships with FUJIFILM Toyama Chemical and MicuRx
as well as funding from CARB-X and Frazier. Together, we look forward to
advancing this exciting drug candidate into human clinical development.”

“Frazier is very pleased to once again back James Ge and his
co-founders, Vernon Jiang, PhD, George H. Talbot, MD, and Paul Eckburg,
MD,” said Patrick Heron, Managing General Partner of Frazier Healthcare
Partners. “We have great confidence in the Recida team based on their
successful development of important antibiotics including doripenem,
ceftaroline, and ceftolozane/tazobactam, as well as significant prior
hands-on experience developing other inhibitors of LpxC.”

About Frazier Healthcare Partners

Founded in 1991, Frazier Healthcare Partners is a leading provider of
growth and venture capital to healthcare companies. With nearly $4.2
billion total capital raised, Frazier has invested in over 170
companies, with investment types ranging from company creation and
venture capital to buyouts of profitable lower-middle market companies.
The firm’s Growth Buyout team invests in healthcare and pharmaceutical
services, medical products and related sectors. The Life Sciences team
invests in therapeutics and related areas that are addressing unmet
medical needs through innovation. Frazier has offices in Seattle, WA and
Menlo Park, CA, and invests broadly across the US, Canada, and Europe.
For more information about Frazier Healthcare Partners, visit the
company’s website at www.frazierhealthcare.com.

Contacts

Liz Park
+1-650-319-1831
[email protected]

error: Content is protected !!